Are the Stem Cells in your Body Drugs? An Update on our Battle to Protect Physician-Patient Rights

Regenerative Sciences vs. FDA

As you may know, our Colorado medical practice has taken a stand for our patients who disagree with FDA’s classification of the cells in their bodies as prescription drugs in our Regenerative Sciences vs. FDA case. This has led us into a legal battle with that has turned into a potential landmark case. Recently, the court has ordered the agency to identify where congress ever authorized it to classify a drug as anything more than a chemical or chemical metabolite. This move apparently caught the eye of K&L Gates, one of the largest legal firms in the world with more than 2,000 attorneys located on three continents in more than 20 countries. Their Legal Insights newsletter is located at this link. Their conclusion?

“Lastly, the Regenerative case has the potential to affect a fundamental aspect of FDA’s regulatory activities. A key element of the case goes to whether an autologous stem cell procedure is a “drug” under the FDCA. The court has raised questions as to how the “device” definition in the FDCA, which excludes articles that operate by chemical action or that are dependent on being metabolized to achieve their intended purpose, could affect whether a stem cell procedure falls within the “drug” definition. It is unclear whether these questions may lead to stem cells being regulated as “devices” instead of “drugs.” However, if the court were to render such a decision and the ruling were upheld on appeal, it would have far reaching implications for other drug/device determinations in the future.”

“The court’s decision will, to a large degree, dictate the types of legal strategies and business models that will be necessary to successfully perform stem cell procedures in the future.”

Learn More About Regenexx® Procedures
Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.
We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

TO TOP